AU2022280269A1 - A super-trail molecule comprising two trail trimers - Google Patents

A super-trail molecule comprising two trail trimers Download PDF

Info

Publication number
AU2022280269A1
AU2022280269A1 AU2022280269A AU2022280269A AU2022280269A1 AU 2022280269 A1 AU2022280269 A1 AU 2022280269A1 AU 2022280269 A AU2022280269 A AU 2022280269A AU 2022280269 A AU2022280269 A AU 2022280269A AU 2022280269 A1 AU2022280269 A1 AU 2022280269A1
Authority
AU
Australia
Prior art keywords
trail
fusion polypeptide
cancer
super
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022280269A
Other languages
English (en)
Other versions
AU2022280269A9 (en
Inventor
Wei Hong
Xinguo QIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING ANXINHUAIDE BIOTECH Co Ltd
Original Assignee
BEIJING ANXINHUAIDE BIOTECH CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING ANXINHUAIDE BIOTECH CO Ltd filed Critical BEIJING ANXINHUAIDE BIOTECH CO Ltd
Publication of AU2022280269A1 publication Critical patent/AU2022280269A1/en
Publication of AU2022280269A9 publication Critical patent/AU2022280269A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Lubricants (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022280269A 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers Pending AU2022280269A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/096498 2021-05-27
CN2021096498 2021-05-27
PCT/CN2022/095472 WO2022247923A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Publications (2)

Publication Number Publication Date
AU2022280269A1 true AU2022280269A1 (en) 2023-11-30
AU2022280269A9 AU2022280269A9 (en) 2023-12-07

Family

ID=84228436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022280269A Pending AU2022280269A1 (en) 2021-05-27 2022-05-27 A super-trail molecule comprising two trail trimers

Country Status (9)

Country Link
US (1) US20240254193A1 (enExample)
EP (1) EP4347665A4 (enExample)
JP (1) JP2024519397A (enExample)
KR (1) KR20240013766A (enExample)
CN (1) CN117396520A (enExample)
AU (1) AU2022280269A1 (enExample)
CA (1) CA3220239A1 (enExample)
IL (1) IL308618A (enExample)
WO (1) WO2022247923A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120475984A (zh) * 2023-01-05 2025-08-12 国家纳米科学中心 Dna-trail复合物及其治疗肿瘤的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CN102898526A (zh) * 2011-07-28 2013-01-30 山东先声麦得津生物制药有限公司 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
PL3145530T3 (pl) * 2014-04-21 2021-10-18 D&D Pharmatech Inc. Agonisty receptora trail w leczeniu chorób zwłóknieniowych
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
WO2017194442A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2018183671A1 (en) * 2017-03-29 2018-10-04 Tdw Group Protein conjugates

Also Published As

Publication number Publication date
US20240254193A1 (en) 2024-08-01
JP2024519397A (ja) 2024-05-10
CN117396520A (zh) 2024-01-12
WO2022247923A1 (en) 2022-12-01
CA3220239A1 (en) 2022-12-01
EP4347665A4 (en) 2025-07-30
EP4347665A1 (en) 2024-04-10
KR20240013766A (ko) 2024-01-30
IL308618A (en) 2024-01-01
AU2022280269A9 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
US10206980B2 (en) IL-15 heterodimeric protein and uses thereof
JP6523331B2 (ja) 単鎖ｔｒａｉｌ受容体アゴニストタンパク質
KR102825098B1 (ko) 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
EP3091028A1 (en) Fibronectin based scaffold proteins having improved stability
BR112019017001A2 (pt) composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo.
US20180346549A1 (en) Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines and Their Use
US20220370563A1 (en) Methods of administration of il-2 receptor agonists
US20230331858A1 (en) Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
KR20180003538A (ko) 듀얼 신호전달 단백질 (dsp) 융합 단백질 및 질환 치료에서의 그것의 이용 방법
US20240101630A1 (en) Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
CN114746106A (zh) 通过肿瘤中使用il-7融合蛋白增加淋巴细胞数的方法
JP7221545B2 (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
WO2022247923A1 (en) A super-trail molecule comprising two trail trimers
JP7690131B2 (ja) Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
KR20240118207A (ko) Sirp1a - 및 cd40l-기반 키메라 단백질
HK40101761A (zh) 包含两个trail三聚体的超trail分子
WO2012019192A2 (en) Cell-permeable molecules as growth factor receptor antagonists
CA3242326C (en) Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2026003203A1 (en) Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
CN108601819B (zh) 用死亡受体激动剂改善系统性硬化症
WO2024050058A2 (en) Ul141 variants, compositions thereof and methods of using the same for cancer immunotherapy
HK40117905A (zh) 用於治疗目的的抗体-脲酶缀合物
HK1258208B (en) Ameliorating systemic sclerosis with death receptor agonists

Legal Events

Date Code Title Description
SREP Specification republished